REGULATORY

MHLW Panel Clears Latuda, 1st Japan-Originated Oligonucleotide; Approval Expected in March

March 2, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A key health ministry advisory panel gave the blessing on February 28 to Sumitomo Dainippon Pharma’s atypical antipsychotic Latuda (lurasidone) and what would be the first Japan-made oligonucleotide therapeutic drug. These drugs, along with a list of other medicines discussed…

To read the full story

Japan OKs Enhertu, 3 Sakigake Drugs, Beovu, Latuda, and More
March 26, 2020

REGULATORY

Government Unveils Four-Chapter Outline for 2026 Honebuto
June 26, 2026
LDP, Ishin Leave Chuikyo Reform to Party Negotiators after Talks Stall
June 26, 2026
Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…